The aim of this rater-blinded randomized study was to evaluate the efficacy and side effects of haloperidol and thioridazine in the treatment of new-onset psychosis in HIV-positive individuals. Participants were 13 men who had no history of psychosis prior to infection with HIV, and whose psychosis was not attributable to delirium or to non-HIV-related organic factors. Participants were evaluated at baseline after at least one month without neuroleptic treatment and then weekly for six weeks of the experimental treatment using several rating scales. The mean daily dose in chlorpromazine equivalents was
124 mg. Both neuroleptics produced modest but significant reduction in overall level of psychosis and in positive symptoms, but not in negative symptoms. All the haloperidol-treated patients developed extrapyramidal side effects and required treatment with anticholinergic medication, whereas three of the five thioridazine-treated patients had noticeable side effects. We make recommendations for the treatment of HIV-associated psychosis with neuroleptics.
fNeuropsychopharmacology 10: 223-229, 1994J The psychiatric sequelae of infection with HIV include depression, anxiety, delirium, dementia, and psycho sis (Fernandez and Levy 1991) . How often patients with no past history of psychosis develop psychotic symp toms subsequent to infection with HIV is not known (Harris et al. 1991; Sewell et al. 1994) . The available in formation suggests that new-onset psychosis in indi viduals infected with HIV, although not common, has serious potential consequences (Miller and Riccio 1990; Boccellari and Dilley 1992) .
Although a causal relationship between the pres ence of HIV in the central nervous system and the de velopment of psychosis has not been established with certainty, there is a growing body of scientifi.c informa tion that supports this notion Mas-liah et al. 1992 ). These fIndings provide a possible ex planation for the development of psychotic symptoms as well as for the reported sensitivity to side effects of psychotropic medications in general (Perry and Jacob sen 1986; Gilmer and Busch 1991) and neuroleptics in particular (Breitbart 1988; Goodkin 1988; Harris et al. 1991; Hriso et al. 1991) .
We found no systematic, prospective studies of the treatment of new-onset psychosis in patients infected with HIV. Information in the literature is currently limited to retrospective chart reviews and case reports, and there is no consensus regarding whether high potency or low-potency neuroleptics are preferable. HIV -infected patients have been reported to be much more sensitive to extrapyramidal side effects (EPS) as sociated with neuroleptic medication, even when the age and gender of the patients are considered . On the other hand, anticholinergic side effects must be minimized in order to avoid exacerbat ing preexisting memory defIcits and to avoid increas ing the risk of candidiasis secondary to dry mucous membranes. Low-potency (more anticholinergic) neu roleptics may also cause confusion when used to treat HIV-infected patients (Harris et al. 1991) . Although high-potency neuroleptics have the disadvantage of be ing much more likely to cause EPS, they provide more antidopaminergic blockage per mg and are less an ticholinergic .
The purpose of our investigation was to study the efficacy and side effects of two commonly used neu roleptics of widely different potencies in the treatment of HIV-associated psychosis. We specifIcally hypothe sized that HIV-infected patients would (1) obtain greater reduction in psychotic symptoms with haloperidol than with thioridazine and (2) experience fewer overall side effects with haloperidol than with thioridazine.
MATERIALS AND METHODS

Subjects
Patients who were included in the present investiga tion came from a comprehensive neuropsychiatric study of new-onset psychosis in 33 patients infected with HIV (Sewell et al. 1994) . That study was, in turn, a part of the San Diego HIV Neurobehavioral Research Center (HNRC), a prospective investigation designed to exam ine the neuropsychiatric consequences of infection with HIV. Patients in the comprehensive neuropsychiatric study of new-onset psychosis complete an extensive assessment that has been previously described (Sewell et al. 1994) .
Patients in the present protocol met the following criteria: (1) age between 18 and 50 years; (2) infection with HIV as determined by ELISA and confIrmed by Western Blot; (3) presence of delusions or prominent NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO. 4 hallucinations; (4) no history of psychosis prior to in fection with HIV; (5) no illicit drug use during three months prior to the onset of psychotic symptoms; (6) absence of delirium as defIned by DSM-III-R (Ameri can Psychiatric Association 1987); (7) neuroleptic-free for at least a month prior to entry; and (8) willing to provide written consent for participation. Seventeen of the 33 patients met selection criteria for the study. The reasons (with N) for the exclusion of patients were: already taking neuroleptic at the time of enrollment and refusing drug-withdrawal (11); refusal to take neurolep tic (4); and absence of psychosis at the time of enroll ment (1). Thirteen patients completed the study (Le., completed at least three sets of weekly ratings) and four dropped out. Three of the dropouts were administra tive, two because urine toxicology studies done during the study revealed amphetamine use and one because severe medical illness prevented the patient from com pleting the clinical ratings. In regards to the two pa tients who were excluded due to amphetamine use, our documentation of amphetamine use led us to conclude that all of the data provided by these patients could have been contaminated by amphetamine use (i.e., perhaps they were using amphetamine even before we discov ered that they were). Regarding the patient who be came too ill to complete the evaluations, only one set of post baseline data was available. The fourth patient did not return after baseline evaluation. The mean (with standard deviation [SO] ) age of the 13 male patients who completed the study was 36 (8) years and the mean years of education completed (with SO) was 13 (2) years.
The majority of these patients were caucasian (n = 11) and were in CDC stage C (AIDS) (n = 7) (Center for Disease Control and Prevention 1992), and their mean absolute serum T4 cell count (with SO) was 308 (258) cells/ill (n = 12). Eleven of the 13 subjects underwent magnetic resonance imaging (MRI) of the brain. None of these images revealed opportunistic infections or neoplasms. Ten of the 13 patients were taking zidovu dine (AZT) at the time of enrollment.
Study Design
Patients entered the study as inpatients or as outpa tients. At the time of the initial contact, all the patients were given the option of receiving psychiatric care from one of the authors (D.D. S. ) and all but two patients ac cepted this option. Using a 1:1 randomization strategy, patients were assigned to treatment with haloperidol or thioridazine. The mean (with standard deviation) starting dose for patients treated with haloperidol was 48 (41) mg, and the mean starting dose for patients treated with thioridazine was 86 (46) mg. Decisions re garding optimal neuroleptic dose were made by 0.0.5. Optimal dose was established clinically by balancing maximum possible reduction in psychotic symptoms against minimum possible side effects. In general, each patient's dose was gradually increased over the six week study period. Patients were not treated with an anti-EPS medication on a prophylactic basis. Patients who developed EPS received benztropine mesylate (n = 8) or trihexyphenidyl hydrochloride (n = 1). Af ter the initial six-week period, patients were seen as of ten as necessary based on their clinical status.
At entry and for the first six weeks of treatment, a rater who was blirlded to neuroleptic assignment com pleted weekly evaluations of each of the patients for efficacy and side effects using the 26-item version of the Brief Psychiatric Rating Scale (BPRS) (Overall 1988) , Scale for the Assessment of Positive Symptoms (SAPS) (Andreasen and Olsen 1982) , Scale for the Assessment of Negative Symptoms (SANS) (Andreasen and Olsen 1982) , Simpson-Angus' EPS rating scale (Simpson and Angus 1970) , and Abnormal Involuntary Movement Scale or AIMS (National Institute of Mental Health 1976). Ratings were completed by one of three individ uals who were from a pool of raters who achieved good interrater reliability as measured by intraclass correla tion coefficients ranging from . 77 to .86 on the rating scales used. The blind was maintained by instructing patients to refrain from discussing their medications with the raters and by excluding the raters from access to the patients' charts. Eight of the 11 patients ran domized to treatment with haloperidol completed the study. The mean maximum daily dose of haloperidol (with SD) for these eight patients was 2.9 (1.4) mg or 120 (61) in mg chlorpromazine equivalents Oeste and Wyatt 1982). Five of the six patients randomized to treat ment with thioridazine completed the protocol. The mean daily dose of thioridazine (with standard devia tion) for these six patients was 145 (76) mg or 131 (68) in mg chlorpromazine equivalents. There was no sig nificant difference in dose in chlorpromazine equiva lents between the two groups.
Statistical Analysis
We compared the 13 patients who completed the treat ment study with the other 20 psychotic patients who did not participate on demographic, clinical rating scale, magnetic resonance imaging, cerebral spinal fluid, and neuropsychological variables to determine if individu als who met criteria for inclusion for and completed the treatment study differed in other ways from those who did not meet inclusion criteria or who did not complete the study. For continuous variables we used two-tailed t-tests unless the assumptions for parametric statistics were not met, in which case we used two-tailed Mann Whitney U-tests. For categorical variables (race and CDC stage) we used chi-square analysis.
The treatment study could be conceptualized as a split-plot design with a drug grouping factor and a NeuroJeptics in HIV-Psychosis 225 repeated measures time factor (baseline and weeks 1 to 6) (Kirk 1982) . Ordinarily this would call for the use of repeated-measures analysis of variance procedure. Missing data, however, led us to select the Newton Raphson (NR) maximum likelihood approach to esti mate parameters and to test the time effect, the drug group effect, and drug group by time interaction effect (Schluchter 1988; Dixon et al. 1990) .
In order to justify the adoption of this approach, we assumed that any missing data were missing at ran dom. In order to run the BMDP statistical software (Dixon et al. 1990 ) version of the NR maximum likeli hood approach (5V), we also had to assume a particu lar structure for the pooled variance-covariance matrix (that is, pooled across the two groups). For each of the rating scales with the exception of the AIMS total score, we assumed equal variances and equal covariances in the pooled variance-covariance matrix, and for the AIMS total score we assumed a banded structure for the variance-covariance matrix (equal variances in the main diagonal of the matrix and equal covariances within paired symmetrical bands above and below the main diagonal of the matrix).
In addition to testing the main effects of drug and time, and the drug by time interaction, we tested the first three orthogonal trend components of the time effect: linear, quadratic, and cubic, and their interac tions with the drug factor. Finally, we correlated the change in BPRS total score with baseline full-scale IQ using Spearman's correlation (rho).
RESULTS
The group of patients who completed the treatment study (n = 13) did not diff er from the group of patients who did not participate in or complete the study (n = 20) on age, race, education, CDC stage, any of the rat ing scale total scores, neuropsychological global scores, absolute T4 count, serum P24 level, or MRI global ratings.
Treatment with neuroleptics resulted in a signifi cant reduction in psychopathology as represented in the BPRS total score and in the BPRS disorganization subscale score which is composed of four items. The mean BPRS total score (68 at baseline and 54 at week six) after rescaling to reflect a minimum possible score of 24 decreased 32% by the end of the study, while the BPRS disorganization subscale score (mean 9.5 at base line) decreased by 62%. Figure 1 depicts the estimated values for the BPRS disorganization subscale score over the first six weeks of treatment. Nonsignificant im provements were observed in BPRS hostility sub scale . In regards to the SAPS total score, whereas the overall time factor was not significant, the linear time compo nent was significant (p = .022). We did not observe im- provements in the BPRS depression subscale or the SANS total. Figure 2 presents the mean SAPS and SANS total scores over the frrst six weeks of treatment. AIMS total score increased nonsignifIcantly over time.
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Haloperidol and thioridazine were similar in that both resulted in a reduction in psychopathology. The reduction in BPRS total was linear in both groups, but the reduction in BPRS disorganization was curvilinear, with the thioridazine-induced reduction occurring ear lier and haloperidol-induced reduction occurring later in the six-week period. There was signifIcantly greater improvement in BPRS hostility subscale score (and also a nonsignifIcantly greater improvement in SAPS total) in the thioridazine group. There was no signifIcant cor relation between full-scale IQ at baseline and change in BPRS total score.
In terms of side effects, none of the patients expe rienced symptomatic orthostasis, although pulse and blood pressure were not measured routinely. All of the eight patients on haloperidol developed EPS and re quired treatment with benztropine. One patient treated with haloperidol developed TD and another patient ex-NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO.4 perienced sedation. Three of the five patients treated with thioridazine had problematic side effects. One pa tient on thioridazine developed EPS and was treated with trihexyphenidyl. A second patient treated with thioridazine experienced weight gain, retrograde ejacu lation, and dry mouth and developed TD. (The patients who developed TD with haloperidol and thioridazine met the published criteria for TD [Schooler and Kane 1982; Jeste and Wyatt 1982] except that the duration of neuroleptic treatment was less than three months.) A third patient treated with thioridazine had noticeable sedation.
DISCUSSION
Our study found a modest but significant improvement in the overall level of HIV-associated psychosis, espe cially positive symptoms, but not in negative symp toms, with six weeks of treatment with either halo peridol or thioridazine. The drug doses were relatively low, with a high incidence of side effects, mostly EPS with haloperidol. Our study has several limitations. The number of patients studied was small and despite our best efforts, we had some missing data. As a result, we selected a statistical method that is applicable even when some data are missing (Schluchter 1988) . This statistical me thod, however, requires caution when used with small samples. The use of a completely randomized proce dure rather than a stratifIed randomization procedure resulted in an imbalance in the size of the two groups which, in turn, resulted in a reduction of power. The patients were not ''blind,'' and there was no placebo period. Clinical and practical issues required us to in form each patient about which drug he was taking. For example, if a patient developed an acute medical prob lem (which was not rare), then the patient needed to provide his physicians with the names and doses of all of the medications that he was taking in order to re ceive an optimal evaluation. It was prudent for us to underestimate the ability of our sick patients to cope with a system of allowing the ''blind'' to be broken in the face of a medical emergency. We had originally planned to have a placebo treatment period; however, the number and intensity of the patients' psychotic symptoms at the time of presentation led us to elimi nate the placebo period from our protocol for ethical and humanitarian reasons.
On the other hand, to our knowledge this is the largest prospective study of the use of neuroleptic medi cation for the treatment of new-onset psychosis in patients infected with HIV. In addition, our protocol included well-defmed subjects and rater-blinded assess ments using well-established rating scales administered by raters who achieved a good level of interrater relia bility.
Although our sample size was small, we should point out that HIV-associated psychosis is not a com mon condition. Furthermore, there are difficulties in studying these patients. In general, our patients faced more than the usual number of impediments to partic ipation in psychiatric clinical research (Sewell et al. 1994 ). The majority of our patients had AIDS, and many had medical symptoms such as weakness and fatigue. Some of our subjects had difficulty participating because of a lack of family support and limited social and finan cial resources.
The mall reason that we chose to study haloperidol and thioridazine was to determine whether high-po tency or low-potency medications were better for the treatment of psychosis in patients infected with HIV. Furthermore, these two neuroleptics belong to diff er ent chemical classes and have different side effect profiles. We chose a six-week study period based on the results of the literature review by Davis et al. (1989) who found that in schizophrenic patients, most of the therapeutic gain occurred within the first six weeks of therapy with antipsychotic medication. We required that patients be neuroleptic-free for at least one month prior to entry in order to allow any nondepot neurolep tic that they might have already received to wash out as much as possible. (None of our patients was on deNeuroJeptics in HIV-Psychosis 227 pot neuroleptics. ) We adopted a flexible dose schedule because of the paucity of information in the literature regarding optimal dose for the treatment of psychotic symptoms in HIV-infected patients. We chose not to use anti-EPS agents prophylactically, because we wanted to avoid the risks associated with the use of anticholiner gic medications, and because we hoped that our study would allow us to estimate the frequency of EPS as sociated with the neuroleptics included in our study. The rating scales included in our design were selected because they have been commonly used, are readily available, and are associated with a large amount of pub lished data regarding their use in other psychiatric co horts.
In general, the nature and time course of neurolep tic response in our patients appeared to resemble those described by Davis et al. (1989) in acute schizophrenic patients. With six weeks of treatment with neurolep tic, the patients in our study experienced improvement in BPRS total score. Importantly, our patients required (or tolerated) a much smaller daily dose of antipsychotic medication than would be used to treat a patient with psychosis in other contexts. Currently, the optimal daily dose level in chlorpromazine equivalents for most" acute patients" with psychosis is 400 to 700 mg (Davis et al. 1989) . The mean maximum dose in chlorpromazine equivalents for our patients was 124 mg. This lower dose is similar to the lower doses used to treat older schizophrenic patients (Jeste et al. 1993 ) and patients with dementia (Wragg and Jeste 1988) . Our fmdings are consistent with the recommendations of Ostrow et al. (1988) and Gilmer and Busch (1991) that psychotic symptoms in HIV -positive patients be treated with low dosages of neuroleptics. Why HIV-positive patients re quire, or more likely, tolerate lower doses of antipsy chotic is unclear, but this could be related to phar macokinetic changes due to chronic diseases (e.g., decreased hepatic clearance).
In a prospective study of 38 patients with AIDS who had organic mental disorders (all with delirium, al though some had delirium and dementia or delirium and some other organic mental disorder) and were treated in an open trial with intravenous haloperidol and lorazepam, Fernandez et al. (1989) found that nearly half of the subjects experienced EPS and that pa tients with delirium along with some other organic men tal disorder appeared to experience EPS more fre quently than those with only delirium. Holmes (1989) described the successful treatment of an AIDS patient with monosymptomatic hypochondriacal psychosis with pimozide (2 mg/day). This patient experienced cogwheel rigidity and akathisia that responded to low dose diazepam. The increased sensitivity of HIV-posi tive patients to neuroleptic-induced EPS suggests that damage to basal ganglionic structures could also be responsible for altered pharmacodynamics.
Our preliminary results do not clearly demonstrate whether low or high potency neuroleptics are better for HIV-positive patients with psychosis. Our results do provide the basis for recommending relatively low doses of neuroleptic coupled with close monitoring for side effects, especially EPS and TD.
Additional information regarding pharmacokinetic and pharmacodynamic changes in patients with HIV associated psychosis is needed. In our study, the mean improvement in total BPRS score over six weeks of treat ment was only 32%, although the mean BPRS disorgan ization subscale score decreased by 62%. It is possible that a longer study period could reveal that HIV -infec ted patients with psychosis experience a greater mag nitude of improvement and continue to improve stead ily. It remains unclear how best to treat the negative symptoms that do not respond to "typical" neurolep tics. Clinical trials of clozapine or methylphenidate may prove useful. 
